Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15284835rdf:typepubmed:Citationlld:pubmed
pubmed-article:15284835lifeskim:mentionsumls-concept:C1704256lld:lifeskim
pubmed-article:15284835lifeskim:mentionsumls-concept:C0033117lld:lifeskim
pubmed-article:15284835lifeskim:mentionsumls-concept:C0475463lld:lifeskim
pubmed-article:15284835lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:15284835lifeskim:mentionsumls-concept:C0475224lld:lifeskim
pubmed-article:15284835lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:15284835pubmed:issue6lld:pubmed
pubmed-article:15284835pubmed:dateCreated2004-11-23lld:pubmed
pubmed-article:15284835pubmed:abstractTextThe objective of this study was to evaluate the possible role of transforming growth factor beta 1 (TGF-beta1) antibodies (ab) for the prevention of fibrotic effects of priapism in a rat model. In total, 30 adult Sprague-Dawley rats were divided into five groups. Priapism with 6 h (group 1), priapism with 6 h+ab (group 2), priapism with 24 h (group 3), priapism with 24 h+ab (group 4) and control (group 5). Priapism was induced with a vacuum erection device and a rubber band was placed at the base of the erect penis. At 1 h after the initiation of priapism, TGF-beta1 antibodies were given intracavernosaly. All rats underwent electrical stimulation of the cavernous nerve after 8 weeks. Intracavernous and systemic blood pressures were measured during the procedure. Rats in group 1 showed significantly higher (intracavernosal pressure (ICP) pressures to cavernous nerve stimulation and had higher ICP/BP ratios when compared to other groups. Similarly, histopathologic examination revealed less fibrosis in group 2, compared with the other groups. Consequently, TGF-beta1 antibodies antagonise the fibrotic effects of TGF-beta1, especially in cases with duration of priapism less than 6 h.lld:pubmed
pubmed-article:15284835pubmed:languageenglld:pubmed
pubmed-article:15284835pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284835pubmed:citationSubsetIMlld:pubmed
pubmed-article:15284835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284835pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15284835pubmed:statusMEDLINElld:pubmed
pubmed-article:15284835pubmed:monthDeclld:pubmed
pubmed-article:15284835pubmed:issn0955-9930lld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:TurkMMlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:KadiogluAAlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:UysalVVlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:NurtenAAlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:SolakogluSSlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:KandiraliEElld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:OzermanBBlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:SanliOOlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:ArmaganAAlld:pubmed
pubmed-article:15284835pubmed:authorpubmed-author:AhmedovIIlld:pubmed
pubmed-article:15284835pubmed:issnTypePrintlld:pubmed
pubmed-article:15284835pubmed:volume16lld:pubmed
pubmed-article:15284835pubmed:ownerNLMlld:pubmed
pubmed-article:15284835pubmed:authorsCompleteYlld:pubmed
pubmed-article:15284835pubmed:pagination492-7lld:pubmed
pubmed-article:15284835pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:meshHeadingpubmed-meshheading:15284835...lld:pubmed
pubmed-article:15284835pubmed:year2004lld:pubmed
pubmed-article:15284835pubmed:articleTitleTGF-beta1 neutralizing antibodies decrease the fibrotic effects of ischemic priapism.lld:pubmed
pubmed-article:15284835pubmed:affiliationIstanbul Faculty of Medicine, University of Istanbul, Istanbul, Turkey.lld:pubmed
pubmed-article:15284835pubmed:publicationTypeJournal Articlelld:pubmed